CFDP1: A Phosphoprotein (Bucentaur) as a Drug Target and Biomarker

Target Name: CFDP1

NCBI ID: G10428

CFDP1

CFDP1: A Phosphoprotein (Bucentaur) as a Drug Target and Biomarker

Phosphoproteins are a type of protein that contains a phosphate group. These proteins play a crucial role in various cellular processes, including cell signaling, protein-protein interactions, and intracellular signaling pathways. One of the most well-known phosphoproteins is Bucentaur, which is a protein that contains a N-terminal phosphate group and is involved in various cellular processes. In this article, we will discuss CFDP1 (phosphoprotein (Bucentaur)) as a drug target and biomarker.

CFDP1: Structure and Function

CFDP1 is a 21-kDa protein that is expressed in various tissues, including muscle, heart, liver, and kidney. It is localized to the endoplasmic reticulum (ER) and can be internalized in the endoplasmic reticulum via the endoplasmic reticulum protein transmembrane transport system (ERTPS). Once internalized, CFDP1 can be processed and degraded by the endoplasmic reticulum protein degradation pathway.

CFDP1 is involved in various cellular processes, including cell signaling, protein-protein interactions, and intracellular signaling pathways. One of the most well-known functions of CFDP1 is its role in the regulation of the myosin ATPase, which is a protein that is involved in the production of force in muscle fibers. CFDP1 has been shown to interact with the myosin ATPase and regulate its activity, which is important for muscle contractions.

CFDP1 has also been shown to be involved in the regulation of cell adhesion. It has been shown to interact with the cadherin protein, which is a protein that is involved in cell-cell adhesion. CFDP1 has been shown to regulate the adhesion of cancer cells to the extracellular matrix (ECM), which is important for cancer cell survival and metastasis.

CFDP1 has also been shown to be involved in the regulation of cell survival. It has been shown to interact with the p53 protein, which is a protein that is involved in the regulation of DNA damage and cell survival. CFDP1 has been shown to regulate the p53 protein in a variety of cellular processes, including cell growth, apoptosis, and survival.

CFDP1 as a Drug Target

CFDP1 has been identified as a potential drug target due to its involvement in various cellular processes that are important for human health. One of the main reasons for identifying CFDP1 as a drug target is its involvement in the regulation of the myosin ATPase, which is a protein that is involved in the production of force in muscle fibers.

Myosin ATPase is a protein that is involved in the production of force in muscle fibers. It is expressed in muscle fibers and is responsible for generating the force that allows muscles to contract. In diseases such as muscular dystrophy and myopathies, the myosin ATPase is often abnormal or missing, which can lead to muscle weakness and dysfunction.

CFDP1 has been shown to interact with the myosin ATPase and regulate its activity. By interacting with the myosin ATPase, CFDP1 can regulate the production of force in muscle fibers, which can lead to muscle weakness and dysfunction.

CFDP1 has also been shown to be involved in the regulation of cell adhesion, which is important for the development and maintenance of tissues. Cell adhesion is the process by which cells stick together to form tissues and organs. CFDP1 has been shown to interact with the cadherin protein, which is a protein that is involved in cell-cell adhesion.

CFDP1 has also been shown to be involved in

Protein Name: Craniofacial Development Protein 1

Functions: May play a role during embryogenesis

The "CFDP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CFDP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets